ADORA2A and schizophrenia: Clinical trials have shown the motor benefits of A2AR antagonists in Parkinson’s patients with high safety profiles [91,94]; however, additional studies are needed to understand the underlying mechanism of adenosine-receptor-mediated control of cognition under normal and disease conditions across neurocognitive disorders, including schizophrenia.